Minimally Invasive Vertebral Compression Fracture Treatments – Market Insights – Global

Despite the short-term negative impact of the COVID-19 pandemic, the global market for MIVCF treatments will show particularly strong growth through 2031, reflecting the moderate growth in the Asia Pacific region as well as sustained growth in the mature US markets, although reimbursement challenges and limited clinical data for newer MIVCF products will continue to hamper the pace of revenue growth to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for MIVCF treatment devices in the global region from 2019 through 2031.

The COVID-19 pandemic has had a negative impact on MIVCF treatments procedure volumes.

To what extent has the COVID-19 pandemic impacted vertebroplasty and vertebral augmentation volumes?

How quickly have associated treatment volumes recovered?

When will each segment of the market return to levels seen prior to the pandemic?

The Asia Pacific MIVCF treatments market will grow moderately.

What factors are driving such moderate market expansion?

How does growth vary in different market segments?

What limiters exist that could impede revenue potential?

Large MNCs continue to dominate the modestly expanding global MIVCF treatment market.

Which competitors lead the MIVCF treatment market globally, and what factors contribute to their success in this space?

What strategies can local and international players implement to capture share in the global MIVCF treatment market?

What types of mergers and acquisitions have occurred in recent years, and how do they affect market shares?

Some MIVCF procedures are slated to decline over the forecast period.

What is causing this decline in procedure volumes, and in which markets?

Table of contents